This feature article is from an interveiw with ECOG-ACRIN Group Co-Chair Peter J. O'Dwyer, MD, who also co-leads the NCI-MATCH precision medicine trial. NCI-MATCH is winding down, but researchers are still analyzing data from its many arms and taking notes for the design of future precision oncology trials based on what this pioneering initiative got right and the challenges it faced.